• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

综述:胰高血糖素在糖尿病低血糖和高血糖发病机制中的作用

Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.

机构信息

Division of Endocrinology, Metabolism, and Lipid Research, Washington University, St. Louis, Missouri 63110, USA.

出版信息

Endocrinology. 2012 Mar;153(3):1039-48. doi: 10.1210/en.2011-1499. Epub 2011 Dec 13.

DOI:10.1210/en.2011-1499
PMID:22166985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3281526/
Abstract

Pancreatic islet α-cell glucagon secretion is critically dependent on pancreatic islet β-cell insulin secretion. Normally, a decrease in the plasma glucose concentration causes a decrease in β-cell insulin secretion that signals an increase in α-cell glucagon secretion during hypoglycemia. In contrast, an increase in the plasma glucose concentration, among other stimuli, causes an increase in β-cell insulin secretion that signals a decrease, or at least no change, in α-cell glucagon secretion after a meal. In absolute endogenous insulin deficiency (i.e. in type 1 diabetes and in advanced type 2 diabetes), however, β-cell failure results in no decrease in β-cell insulin secretion and thus no increase in α-cell glucagon secretion during hypoglycemia and no increase in β-cell insulin secretion and thus an increase in α-cell glucagon secretion after a meal. In type 1 diabetes and advanced type 2 diabetes, the absence of an increment in glucagon secretion, in the setting of an absent decrement in insulin secretion and an attenuated increment in sympathoadrenal activity, in response to falling plasma glucose concentrations plays a key role in the pathogenesis of iatrogenic hypoglycemia. In addition, there is increasing evidence that, in the aggregate, suggests that relative hyperglucagonemia, in the setting of deficient insulin secretion, plays a role in the pathogenesis of hyperglycemia in diabetes. If so, abnormal glucagon secretion is involved in the pathogenesis of both hypoglycemia and hyperglycemia in diabetes.

摘要

胰岛 α 细胞胰高血糖素的分泌对胰岛 β 细胞胰岛素的分泌有严格的依赖性。通常,血糖浓度降低会导致 β 细胞胰岛素分泌减少,从而在低血糖时信号增加 α 细胞胰高血糖素分泌。相比之下,血糖浓度升高(以及其他刺激因素)会导致 β 细胞胰岛素分泌增加,从而在餐后信号减少或至少不变 α 细胞胰高血糖素分泌。然而,在绝对内源性胰岛素缺乏(即 1 型糖尿病和晚期 2 型糖尿病)中,β 细胞衰竭导致β细胞胰岛素分泌没有减少,因此在低血糖期间没有增加 α 细胞胰高血糖素分泌,也没有增加β细胞胰岛素分泌,因此在餐后增加 α 细胞胰高血糖素分泌。在 1 型糖尿病和晚期 2 型糖尿病中,在胰岛素分泌没有减少、交感肾上腺活性增加而胰高血糖素分泌没有增加的情况下,血糖浓度下降时缺乏胰高血糖素分泌的增加,在医源性低血糖的发病机制中起着关键作用。此外,越来越多的证据表明,在胰岛素分泌不足的情况下,相对高血糖素血症总体上可能在糖尿病高血糖的发病机制中起作用。如果是这样,异常的胰高血糖素分泌可能参与了糖尿病低血糖和高血糖的发病机制。

相似文献

1
Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes.综述:胰高血糖素在糖尿病低血糖和高血糖发病机制中的作用
Endocrinology. 2012 Mar;153(3):1039-48. doi: 10.1210/en.2011-1499. Epub 2011 Dec 13.
2
Inhibition of glucagon secretion.抑制胰高血糖素分泌。
Adv Pharmacol. 2005;52:151-71. doi: 10.1016/S1054-3589(05)52008-8.
3
Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus.肾上腺素介导的β-肾上腺素能机制在胰岛素依赖型糖尿病低血糖葡萄糖对抗调节及低血糖后高血糖中的作用
J Clin Invest. 1982 Feb;69(2):315-26. doi: 10.1172/jci110455.
4
Co-impairment of autonomic and glucagon responses to insulin-induced hypoglycemia in dogs with naturally occurring insulin-dependent diabetes mellitus.自发性胰岛素依赖型糖尿病犬对胰岛素诱导性低血糖的自主神经和胰高血糖素反应受损。
Am J Physiol Endocrinol Metab. 2020 Dec 1;319(6):E1074-E1083. doi: 10.1152/ajpendo.00379.2020. Epub 2020 Oct 12.
5
The Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes.α 细胞在胰岛功能和血糖稳态中的作用:健康与 2 型糖尿病。
J Mol Biol. 2020 Mar 6;432(5):1367-1394. doi: 10.1016/j.jmb.2020.01.004. Epub 2020 Jan 15.
6
Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.葡萄糖依赖性促胰岛素多肽:对人体胰岛素和胰高血糖素分泌的影响
Dan Med J. 2016 Apr;63(4).
7
Molecular pathways underlying the pathogenesis of pancreatic alpha-cell dysfunction.胰腺α细胞功能障碍发病机制的分子途径。
Adv Exp Med Biol. 2010;654:421-45. doi: 10.1007/978-90-481-3271-3_18.
8
Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes.增加胰岛素分泌的减少量可改善晚期2型糖尿病患者胰高血糖素对低血糖的反应。
Diabetes Care. 2005 Nov;28(11):2691-6. doi: 10.2337/diacare.28.11.2691.
9
Role of glucagon in the pathogenesis of diabetes: the status of the controversy.胰高血糖素在糖尿病发病机制中的作用:争议现状
Metabolism. 1978 Nov;27(11):1691-709. doi: 10.1016/0026-0495(78)90291-3.
10
Somatostatin receptor type 2 antagonism improves glucagon counterregulation in biobreeding diabetic rats.生长抑素受体 2 拮抗剂改善生物培育糖尿病大鼠的胰高血糖素抵抗调节。
Diabetes. 2013 Aug;62(8):2968-77. doi: 10.2337/db13-0164. Epub 2013 Apr 29.

引用本文的文献

1
Evaluating the role of alpha cell dysregulation in the progression to type 2 diabetes using mathematical simulations.使用数学模拟评估α细胞失调在2型糖尿病进展中的作用。
Diabetologia. 2025 Sep 9. doi: 10.1007/s00125-025-06524-1.
2
Quantification of glucagon and oxyntomodulin by protein precipitation-immunoaffinity enrichment-LC-MS/MS.通过蛋白质沉淀-免疫亲和富集-LC-MS/MS对胰高血糖素和胃泌酸调节素进行定量分析。
J Mass Spectrom Adv Clin Lab. 2025 Apr 11;36:37-45. doi: 10.1016/j.jmsacl.2025.04.002. eCollection 2025 Apr.
3
Target Discovery to Diabetes Therapy-TXNIP From Bench to Bedside With NIDDK.从糖尿病治疗的靶点发现到临床应用——TXNIP从实验室到床边的转化历程(美国国立糖尿病、消化和肾脏疾病研究所资助)
Endocrinology. 2025 Mar 24;166(5). doi: 10.1210/endocr/bqaf055.
4
The Promise of Adjunct Medications in Improving Type 1 Diabetes Outcomes: Glucagon-Like Peptide Receptor Agonists.辅助药物在改善1型糖尿病治疗效果方面的前景:胰高血糖素样肽受体激动剂
J Diabetes Sci Technol. 2025 Mar;19(2):311-320. doi: 10.1177/19322968241309896. Epub 2024 Dec 31.
5
Autophagy-lysosome pathway in insulin & glucagon homeostasis.胰岛素与胰高血糖素稳态中的自噬-溶酶体途径
Front Endocrinol (Lausanne). 2025 Feb 10;16:1541794. doi: 10.3389/fendo.2025.1541794. eCollection 2025.
6
Decne., an endemic and rare subshrub from Arabian desert: antidiabetic and antihyperlipidemic effects of leaf hydroethanolic extracts.Decne.,一种来自阿拉伯沙漠的地方性珍稀亚灌木:叶水乙醇提取物的抗糖尿病和抗高血脂作用。
Front Pharmacol. 2025 Feb 10;16:1537071. doi: 10.3389/fphar.2025.1537071. eCollection 2025.
7
The role of GABA in type 1 diabetes.γ-氨基丁酸在1型糖尿病中的作用。
Front Endocrinol (Lausanne). 2024 Nov 15;15:1453396. doi: 10.3389/fendo.2024.1453396. eCollection 2024.
8
Hyperglucagonemia and glucagon hypersecretion in early type 2 diabetes result from multifaceted dysregulation of pancreatic mouse α-cells.2型糖尿病早期的高胰高血糖素血症和胰高血糖素分泌过多是由胰腺小鼠α细胞的多方面失调引起的。
Pflugers Arch. 2025 Feb;477(2):207-221. doi: 10.1007/s00424-024-03045-5. Epub 2024 Nov 27.
9
Antidiabetic potential of aqueous extract: insights into pancreatic lipase inhibition, antioxidant activity, antiglycation at multiple stages and anti-inflammatory effects.水提取物的抗糖尿病潜力:对胰腺脂肪酶抑制、抗氧化活性、多阶段抗糖化及抗炎作用的见解
Front Pharmacol. 2024 Oct 30;15:1443311. doi: 10.3389/fphar.2024.1443311. eCollection 2024.
10
Combination of GLP-1 Receptor Activation and Glucagon Blockage Promotes Pancreatic -Cell Regeneration in Type 1 Diabetic Mice.胰高血糖素样肽-1受体激活与胰高血糖素阻断相结合促进1型糖尿病小鼠胰岛β细胞再生
J Diabetes Res. 2021 Nov 25;2021:7765623. doi: 10.1155/2021/7765623. eCollection 2021.

本文引用的文献

1
Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes.短期给予胰高血糖素受体拮抗剂 LY2409021 可降低健康人和 2 型糖尿病患者的血糖。
Diabetes Obes Metab. 2015 Apr;17(4):414-22. doi: 10.1111/dom.12446. Epub 2015 Mar 2.
2
First proof of pharmacology in humans of a novel glucagon receptor antisense drug.新型胰高血糖素受体反义药物在人体中的首次药理学验证。
J Clin Pharmacol. 2015 Mar;55(3):298-306. doi: 10.1002/jcph.396. Epub 2014 Sep 15.
3
Physiologic action of glucagon on liver glucose metabolism.胰高血糖素对肝脏葡萄糖代谢的生理作用。
Diabetes Obes Metab. 2011 Oct;13 Suppl 1(Suppl 1):118-25. doi: 10.1111/j.1463-1326.2011.01454.x.
4
Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?葡萄糖对胰高血糖素分泌的调节作用:旁分泌、固有还是两者兼有?
Diabetes Obes Metab. 2011 Oct;13 Suppl 1:95-105. doi: 10.1111/j.1463-1326.2011.01450.x.
5
Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes.2 型糖尿病患者中脉冲式胰岛素和胰高血糖素分泌之间的负相关关系丧失。
Diabetes. 2011 Aug;60(8):2160-8. doi: 10.2337/db11-0251. Epub 2011 Jun 15.
6
Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance.肥胖 2 型糖尿病患者 metreleptin 的疗效:瘦素耐受的细胞和分子途径。
Diabetes. 2011 Jun;60(6):1647-56. doi: 10.2337/db10-1791.
7
Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes.重组人瘦素治疗不能改善 2 型糖尿病肥胖患者的胰岛素作用。
Diabetes. 2011 May;60(5):1474-7. doi: 10.2337/db10-1302. Epub 2011 Mar 16.
8
Partial inhibition of insulin secretion results in glucose intolerance but not hyperglucagonemia.胰岛素分泌部分抑制导致葡萄糖不耐受但不会引起高胰高血糖素血症。
Diabetes. 2011 Apr;60(4):1324-8. doi: 10.2337/db10-1586. Epub 2011 Mar 4.
9
Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice.胰高血糖素受体敲除可预防小鼠胰岛素缺乏型 1 型糖尿病。
Diabetes. 2011 Feb;60(2):391-7. doi: 10.2337/db10-0426.
10
Leptin downregulates expression of the gene encoding glucagon in alphaTC1-9 cells and mouse islets.瘦素可下调 alphaTC1-9 细胞和小鼠胰岛中编码胰高血糖素的基因表达。
Diabetologia. 2011 Apr;54(4):843-51. doi: 10.1007/s00125-010-2024-1. Epub 2011 Jan 14.